{"prompt": "['saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered', 'through an IV administration set with a 0.2- or 0.22-m in-line filter. Add 30.0 mL of durvalumab (i.e. 1500 mg', 'of durvalumab) to the IV bag. The IV bag size should be selected such that the final concentration is within 1 to', '15 mg/mL. Mix the bag by gently inverting to ensure homogeneity of the dose in the bag.', 'If weight falls to VI 30 kg weight-based dosing at 20 mg/kg will be administered using an IV bag containing', '0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL,', 'and delivered through an IV administration set with a 0.2- - or 0.22-m in-line filter.', 'Standard infusion time is 1 hour. In the event that there are interruptions during infusion, the total allowed', 'infusion time should not exceed 8 hours at room temperature.', 'Do not co-administer other drugs through the same infusion line.', 'The IV line will be flushed with a volume of IV diluent equal to the priming volume of the infusion set used', 'after the contents of the IV bag are fully administered, or complete the infusion according to institutional policy', 'to ensure the full dose is administered and document if the line was not flushed.', 'If either preparation time or infusion time exceeds the time limits a new dose must be prepared from new vials.', 'Durvalumab does not contain preservatives, and any unused portion must be discarded.', '6.2. Description, packaging and labeling of tremelimumab', 'Tremelimumab will be supplied by FFCD as a 400-mg or a 25-mg vial solution for infusion after dilution.', 'The solution contains 20 mg/mL tremelimumab, 20 mM histidine/histidine hydrochloride, 222 mM trehalose', 'dihydrate, 0.27 mM disodium edetate dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of', '5.5 and a density of 1.034 g/mL.', 'The nominal fill volume is 20.0 mL for the 400-mg vial and 1.25 mL for the 25-mg vial. Investigational product', 'vials are stored at 2\u00b0C to 8\u00b0C and must not be frozen. Drug product should be kept in original container until use', 'to prevent prolonged light exposure.', \"The dose of tremelimumab for administration must be prepared by the Investigator's or site's designated\", 'investigational product manager using aseptic technique. Total time from needle puncture of the tremelimumab', 'vial to the start of administration should not exceed:', '24 hours at 2\u00b0C to 8\u00b0C', '4 hours at room temperature', 'Infusion solution must be allowed to equilibrate to room temperature prior to commencement of administration.', 'A dose of 75 mg (for patients >30kg in weight) will be administered using an IV bag containing 0.9% (w/v)', 'saline or 5% (w/v) dextrose, with a final tremelimumab concentration ranging from 0.10 to 10 mg/mL, and', 'delivered through an IV administration set with a 0.2- or 0.22-m in-line filter. Add 3.8 mL (ie,75 mg of', 'tremelimumab, with the dose volume rounded to the nearest tenth mL) to the IV bag. The IV bag size should be', 'selected such that the final concentration is within 0.10 to 10 mg/mL. Mix the bag by gently inverting to ensure', 'homogeneity of the dose in the bag.', 'If weight falls to < 30 kg, weight-based dosing at 1 mg/kg will be administered using an IV bag containing 0.9%', '(w/v) saline or 5% (w/v) dextrose, with a final tremelimumab concentration ranging from 0.10 to 10 mg/mL,', 'and delivered through an IV administration set with a 0.2- or 0.22-m in-line filter.', 'Standard infusion time is 1 hour. In the event that there are interruptions during infusion, the total allowed', 'infusion time should not exceed 8 hours at room temperature.', 'Do not co-administer other drugs through the same infusion line.', 'The IV line will be flushed with a volume of IV diluent equal to the priming volume of the infusion set used', 'after the contents of the IV bag are fully administered, or complete the infusion according to institutional policy', 'to ensure the full dose is administered and document if the line was not flushed.', 'If either preparation time or infusion time exceeds the time limits a new dose must be prepared from new vials.', 'Tremelimumab does not contain preservatives, and any unused portion must be discarded.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 20 de 123']['6.3. FOLFIRI + durvalumab (1st and 2nd steps of the safety run-in phase and Arm A)', 'No prophylactic treatment is necessary for durvalumab.', 'Prophylactic treatment for FOLFIRI is administered according the standard centre clinical practice.', 'Primary prophylaxis with G-CSF is not necessary but is allowed, notably if febrile neutropenia occurred during', \"first-line therapy. Secondary prophylaxis with G-CSF is left up to the investigator's judgment and according to\", \"hematological toxicity of chemotherapy and the patient's clinical characteristics.\", 'Recommendation on dose capping: Centers will perform dose capping according to their habits. It might be', 'recommended to do not cap the dose at 2m\u00b2 if the patient presents an important muscle mass. However, if the', 'patient presents an important fat mass, a 2m\u00b2 capping might be considered.', '- Durvalumab: 1500 mg by 1-hour IV infusion - 1 course every 4 weeks (= 1 cycle)', '- FOLFIRI - one course every 2 weeks:', '- Irinotecan: 180 mg/m\u00b2 by 2-hours IV infusion', '- Folinic acid: 400 mg/m\u00b2 (or 200 mg/m\u00b2 if Elvorine) by 2-hours IV infusion', '- 5-FU bolus: 400 mg/m\u00b2 by 10-minutes IV bolus', '- Continuous 5-FU: 2400 mg/m\u00b2 by 46-hours IV infusion', 'FOLFIRI - every 2 weeks', '5-FU bolus', '400 mg/m\u00b2', 'Irinotecan', '180 mg/m\u00b2 -', 'IV infusion', 'Every 4 weeks', 'Durvalumab', 'Folinic acid', '1500 mg', '400 mg/m\u00b2 IV', 'Continuous 5-FU', 'IV infusion', 'infusion', '2400 mg/m\u00b2 - IV infusion', '(or 200 mg/m\u00b2 if', 'Elvorine)', '1 hour', '2 hours', '46h (Day 1-2)', 'A minimum of 30 minutes should be observed between durvalumab and FOLFIRI administration.', '6.4. FOLFIRI + durvalumab + tremelimumab (2nd step of the safety run-in phase and Arm', 'B)', 'No prophylactic treatment is necessary for durvalumab and tremelimumab.', 'Prophylactic treatment for FOLFIRI is administered according the standard center clinical practice.', 'Primary prophylaxis with G-CSF is not necessary but is allowed, notably if febrile neutropenia occurred during', \"first-line therapy. Secondary prophylaxis with G-CSF is left up to the investigator's judgement and according to\", \"haematological toxicity of chemotherapy and the patient's clinical characteristics.\", 'Recommendation on irinotecan, folinic acid, 5-FU bolus and continuous 5-FU dose capping. Centers will', 'perform dose capping according to their habits. It might be recommended to do not cap the dose at a body', 'surface area of 2 m\u00b2 if the patient presents an important muscle mass. However, if the patient presents an', 'important fat mass, a 2 m\u00b2 capping might be considered.', '6.4.1. For the 2nd step of the safety run-in phase', '- Tremelimumab: 75 mg by 1-hour IV infusion - 1 cycle (i.e. every 4 weeks) for only 4 cycles', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 21 de 123']\n\n###\n\n", "completion": "END"}